SCHEDULE 13G/A: BlackRock Reduces Stake in C4 Therapeutics to 2.5%
Schedule 13G Amendment
BlackRock, Inc. has reduced its beneficial ownership in C4 Therapeutics, Inc. to 2.5% of the common stock, as disclosed in an amended Schedule 13G filing.
Summary
- BlackRock, Inc. reported beneficial ownership of 1,756,613 shares of C4 Therapeutics, Inc. common stock.
- This ownership represents 2.5% of the total outstanding common stock of C4 Therapeutics, Inc.
- BlackRock holds sole voting power over 1,749,196 shares and sole dispositive power over 1,756,613 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previously reported ownership level, specifically a reduction to below the 5% threshold.
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The reduction in BlackRock's beneficial ownership from over 5% to 2.5% is generally perceived as a negative signal, indicating a large institutional investor has reduced its exposure to the company.
Negatives
- BlackRock, Inc. has reduced its beneficial ownership in C4 Therapeutics, Inc. to 2.5% of the common stock, implying a reduction from a previously held stake of over 5%.
Risks
- The reduction in a significant institutional investor's stake could signal reduced confidence in the company's future prospects, potentially impacting investor sentiment and share price.
Future Outlook
NA
Industry Context
This filing reflects a portfolio adjustment by a major institutional asset manager, BlackRock, in the biotechnology or pharmaceutical sector (C4 Therapeutics is a biopharmaceutical company). Such adjustments can influence market perception of the underlying company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, appointing several individuals as attorneys-in-fact for executing and filing ownership or control-person reporting requirements with regulatory authorities. This new power of attorney revokes the previous one dated April 30, 2023. | 2025-01-21 | Streamlines BlackRock's internal process for SEC and other regulatory filings related to ownership disclosures. |
Stakeholder Impact
- Shareholders: The reduction in a major institutional investor's stake could lead to decreased investor confidence and potentially negative share price movement.
- Management: May face questions regarding the reasons for the institutional divestment.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-07-16 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, C4 Therapeutics, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.